Arkolith/Insider Trading/NKGN/Form 4

Graf James A

Interim CFO, 10% OwnerNKGen Biotech, Inc. (NKGN) · full profile →Form 4 · filed Dec 26, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 20, 2024Other(J)64K—$02.1M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 20, 2024Disposed to issuer(D)93K——96K
Dec 20, 2024Disposed to issuer(D)758K——1.1M

Transaction Codes

J
Other acquisition / disposition
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-24-112773) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML